EMA and academia develop future framework of collaboration
London, UK, June 15, 2016
On June 15, 2016 the European Medicines Agency (EMA) held a workshop with representatives of academia to discuss the future framework of collaboration. More than 40 participants from European Research Infrastructures, European learned societies and universities attended the event. The workshop participants explored possibilities how to further strengthen the longstanding relationship between regulatory authorities and academia. Through closer interaction, both sides intend to benefit more extensively from each other’s expertise: The academic sector will increase their understanding of the regulatory environment which will ultimately simplify the development of patient-focused medicines. At the same time, the EU medicines regulatory network expects valuable insights into latest challenges and scientific developments to assess innovative medicines based on up-to-date knowledge.
The final collaboration framework will be presented at the EMA’s Management Board meeting in December 2016. The overall aim is to ensure the development of innovative medicines in order to promote public health.
MYOCURE follows the strategic considerations and strengthens close interaction between EMA and academia to maximise the impact of its work. The interdisciplinary composition of the MYOCURE consortium includes strong regulatory expertise and pro-active involvement of EMA as an elementary part of the work plan.
Please find more information on the workshop here.